Summary
This prediction ended on 08.08.17 with a price of €13.53. The BUY prediction by melinda finished with a performance of 11.41%. melinda has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 4.652% | 4.652% | -41.565% | -71.923% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by melinda for this prediction
In the thread Evotec AG diskutieren
EVOTEC
Evotec übernimmt deutsche Aptuit für 256 Millionen Euro in den Vereinigten Staaten basiert
30. Juli (Reuters) - Evotec AG: Evotec Aptuit zu erwerben, um die Führung in externer Innovation erstreckt. Eine Auswertung von etwa 256 Millionen Euro zahlbar in Bilanz Bargeld in Höhe von Evotec und Fremdfinanzierung zu sehr attraktiven Konditionen.